News in English
Swedish company Bioarctic has recently enjoyed great success in the field of Alzheimer’s disease, receiving full approval in the US for the drug lecanemab this summer. The company is also active in other therapeutic areas.
The patent now approved by the Japanese Patent Office (JPO) is for the drug candidate Ban0805, designed to stop or delay the progression of Parkinson’s disease.
The candidate involves a monoclonal antibody which, according to the company’s description, ‘selectively binds to and eliminates pathological aggregated forms called oligomers and protofibrils while protecting the physiological monomeric form of alpha-synuclein’.
A conducted phase I study has supported the continued development of the drug candidate in phase II with dosing once a month.
“The patent further strengthens Bioarctic’s patent portfolio and supports our important work to develop potential treatments for Parkinson’s disease and other synucleinopathies,” says the company’s CEO, Gunilla Osswald, in a press release.
The patent runs until 2041, with an option for extending the patent period until 2046.